Inhibitors of .beta.-glucuronidase and their use in the treatmen

Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

514 24, 514 25, 514 42, 536 41, 536 172, 536 179, 536 182, 536 221, 536 291, 536 53, 536 54, 536 55, C07H 504, C07H 100, A61K 3170

Patent

active

058178007

ABSTRACT:
Compounds of the formulae I and II ##STR1## are suitable for the suppression of tumor growth and of tumor metastasis.

REFERENCES:
patent: 3903289 (1975-09-01), Magee
patent: 4990500 (1991-02-01), Vertesy et al.
patent: 5231185 (1993-07-01), Ganem et al.
patent: 5412082 (1995-05-01), Wittman et al.
Roland Hoos et al., "148. Synthesis and Enzymatic Evaluation of Substrates and Inhibitors of .beta.-Glucuronidases," Helvetica Chimica Acta, vol. 79, pp. 1757-1783 (1996).
Y. Naparstek et al., "Activated T Lymphocytes Produce a Matrix-Degrading Heparan Sulphate Endoglycosidade", Nature, 310:241-244 (1984).
T. Niwa et al., "a New Potent .beta.-Glucuronidase Inhibitor, D-Glucaro-.delta.-lactam Derived from Nojirimycin", J. Biochem, 72(1):207-211 (1972).
Nakajima et al., "Heparanases and Tumor Metastasis", J. of Cellular Biochemistry, 36:157-167 (1988).

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Inhibitors of .beta.-glucuronidase and their use in the treatmen does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inhibitors of .beta.-glucuronidase and their use in the treatmen, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of .beta.-glucuronidase and their use in the treatmen will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-79339

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.